학술논문
Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: a case report with literature analysis
Document Type
Report
Author
Source
Molecular and Clinical Oncology. March 2017, Vol. 6 Issue 3, p389, 8 p.
Subject
Language
English
ISSN
2049-9450
Abstract
Introduction Hepatocellular carcinoma (HCC) is the most common primary liver cancer, with an incidence of approximately 780,000 new cases worldwide each year. It is also the third largest cause of [...]
Hepatocellular carcinoma (HCC) is the principal primary liver tumor, representing the third largest cause of cancer-associated death worldwide. The actual reference standard systemic treatment for advanced HCC is represented by sorafenib, a multi-targeted orally active small-molecule tyrosine kinase inhibitor. Sorafenib has exhibited a good general safety profile in multiple clinical trials. However, adverse drug-associated events are common, occasionally severe, and special attention should be paid to cardiovascular adverse events, particularly in patients with risk factors or known heart disease. In the present study, the case of a patient with no known cardiovascular risk factors affected by highly enhancing advanced HCC in cirrhotic liver, who died during successful sorafenib monotherapy, is reported. Key words: hepatocellular carcinoma, sorafenib, tyrosine kinase inhibitor, vascular endothelial growth factor, sudden cardiac death, case report
Hepatocellular carcinoma (HCC) is the principal primary liver tumor, representing the third largest cause of cancer-associated death worldwide. The actual reference standard systemic treatment for advanced HCC is represented by sorafenib, a multi-targeted orally active small-molecule tyrosine kinase inhibitor. Sorafenib has exhibited a good general safety profile in multiple clinical trials. However, adverse drug-associated events are common, occasionally severe, and special attention should be paid to cardiovascular adverse events, particularly in patients with risk factors or known heart disease. In the present study, the case of a patient with no known cardiovascular risk factors affected by highly enhancing advanced HCC in cirrhotic liver, who died during successful sorafenib monotherapy, is reported. Key words: hepatocellular carcinoma, sorafenib, tyrosine kinase inhibitor, vascular endothelial growth factor, sudden cardiac death, case report